Chargement en cours...
Strategies and Endpoints of Antifibrotic Drug Trials
There is an urgent need to develop antifibrotic therapies for chronic liver disease, and to clarify which endpoints in antifibrotic trials will be acceptable to regulatory agencies. AASLD sponsored an endpoints conference to help accelerate the efficient testing of antifibrotic agents and to develop...
Enregistré dans:
| Publié dans: | Hepatology |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4515973/ https://ncbi.nlm.nih.gov/pubmed/25626988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.27720 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|